Home › Wrist Fractures › NCT06179004
Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery
Randomized Controlled Trial of Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age greater than or equal to 18 * Scheduled for orthopedic wrist surgery at University of North Carolina at Chapel Hill. Exclusion Criteria: * Contraindications to regional anesthesia * Emergent surgery Open fractures will be treated emergently and will not allow adequate lead time for enrollment in this study. Also, open fractures are usually accompanied by other traumatic injuries that would confound the pain related outcomes in this study. * Significant peripheral neuropathy or neurological disorder affecting the upper extremity * Pregnancy Pregnant women have physiologic changes that make them more sensitive to local anesthetics. That would introduce a confounding element in interpreting the effectiveness of the peripheral nerve blocks being studied. * Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
About the study
Orthopedic wrist procedures often cause significant postoperative pain. A supraclavicular nerve block is an effective and proven method to help reduce postoperative pain and decrease opioid use around the time of upper extremity surgery. Liposomal bupivacaine (Exparel) has been approved for use around the brachial plexus, but its analgesic efficacy has limited data. The investigators' goal is to evaluate the effectiveness of Exparel as compared to plain bupivacaine. The investigators hope to ensure the quality of pain control around the time of distal radius fracture repair and reduce the variability of care at the investigators institution by prospectively and rigorously collecting perioperative data during this study.
What is being tested
- Liposomal bupivacaine (drug)
- Bupivacaine Hydrochloride (drug)
Sponsor: University of North Carolina, Chapel Hill · Participants: 100 · Started: Apr 10, 2024
Contact the study team
- Jay Schoenherr, MD · Phone: 9199515062
Official record on ClinicalTrials.gov — NCT06179004
Locations in the U.S.
| North Carolina | UNC Chapel Hill, Chapel Hill |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.